ipilimumab
bms
['melanoma']
from #esmo2022, promising phase 3 clinical trial data was presented where tumor-infiltrating lymphocytes (tils) showed clinical efficacy even in advanced melanoma patients who were refractory to anti-pd-1 treatment. 
#Medicine| Dir. & Host @MedNewsWeek| Research #Oncology #COVID19 #Immunotherapy #celltherapy #tcellrx #CART #bmtsm| About Me: https://t.co/PZG3UGoJrh